Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ligand Pharmaceuticals
Age
48–75
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Postmenopausal women with low bone density (osteopenia) and screening labs, pelvic ultrasound, mammogram without significant findings
You may not be if
Presence of metabolic bone disease, fractures, blood clots, or recent cancer.
Any use of selective estrogen receptor modulators, investigational drugs, or recent use of osteoporosis treatments, certain hormones, or medication for blood clots or seizures.
Clareo Health | Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
